Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.
There has been unprecedented growth in new therapeutic approaches for the treatment of systemic lupus erythematosus (SLE). These approaches include re-evaluation of the doses and duration of therapy with traditional agents, including intravenous cyclophosphamide and azathioprine. Drugs that were developed for other uses are being applied to specific SLE manifestations, and have spurred larger scale trials for overall disease activity. In addition, several new agents show promise in clinical trials; many have safer toxicity profiles than do traditional therapies. Some of these agents have multiple immunomodulatory effects, whereas others interfere with a specific immunologic process in one of the pathogenetic pathways of SLE activity.
Dooley
Mary Anne
MA
bgbaldwi@med.unc.edu
Ginzler
Ellen M
EM
D065095:Calcineurin Inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011687:Purines / Q000037:antagonists & inhibitors
D065095:Calcineurin Inhibitors; D016207:Cytokines; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D011687:Purines